Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

Cochlear implant changes Magteld's world
2009-11-06

The microphone is ready for Magteld Smith’s (second from the left) first radio interview after the cochlear implant was switched on by Mr Henk Wolmarans (right) of MedEl. With them are, from the left: Ms Vicki Fourie, Deaf Miss SA, Ms Eunika Smith from the SABC and Prof. Jonathan Jansen.
Photo: Leatitia Pienaar


Magteld Smith gave her first steps towards the world of the hearing when her cochlear implant was switched on in the Universitas Hospital this week.

A whole team was there to share her joy and disbelief and amazement the moment she could hear noises, voices and conversations. Among them were the Rector and Vice-Chancellor of the University of the Free State (UFS), Prof. Jonathan Jansen, and the acting dean of the Faculty of Heath Sciences at the UFS, Prof. Gert van Zyl.

“I can hear my own voice! I haven’t heard it for a long time. My wish is that every deaf child can get something like this,” she said while prodding Prof. Jansen to speak so that she can hear his voice.

Magteld is working at the university's Centre for Health Systems Research and Development and was deaf since birth. She lost her last bit of hearing due to meningitis last year. Her hearing aids could then not assist her to communicate and a cochlear implant was the only option.

A donation by the Austrian company MedEl made the implant possible. Prof. André Claassen, Head of the Department of Otorhinolaryngology at the UFS, says MedEl was also instrumental in the establishment of the implant programme at the Universitas Hospital and sponsored the first five implants at a total cost of R1 million.

Prof. Claassen says 27 implants have already been done here, but it came to an abrupt halt due to a lack of funds. Strong hearing aids are expensive and cochlear implants are even more expensive at R200 000 each. People with hearing disabilities must be identified at an early age as the brain’s ability to learn sound and voice diminishes after the age of three.
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept